Development of an amoebic gill disease vaccine to protect Atlantic salmon

该项目旨在确定候选疫苗抗原，并生产一种针对阿米巴鳃病（AGD）的实验性疫苗，这将有利于塔斯马尼亚和国际大西洋鲑鱼水产养殖业。AGD是影响塔斯马尼亚大西洋鲑鱼水产养殖的最重要的健康问题。在过去的十年中，AGD已经成为数十亿美元的全球大西洋鲑鱼产业的合法健康威胁。在AGD在最大的大西洋鲑鱼生产国完全建立自己之前，需要一个解决方案。该项目的预期成果是开发出一种商业疫苗，这将使澳大利亚和国际水产养殖业受益匪浅。

This project aims to identify candidate vaccine antigens and produce an experimental vaccine against amoebic gill disease (AGD) that will benefit the Tasmanian and international Atlantic salmon aquaculture industries. AGD is the most significant health problem affecting Atlantic salmon aquaculture in Tasmania. In the last decade, AGD has become a legitimate health threat to the multibillion dollar global Atlantic salmon industry. A solution is needed before AGD fully establishes itself in the largest Atlantic salmon producing nations. The expected outcome of this project is the development of a commercial vaccine that should significantly benefit the Australian and international aquaculture industries.